Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

ImmunoGen Shares Drop on Roche Drug Royalty Payments


The stock falls after investors get a peak at the royalty rate structure that pharma giant Roche will pay to ImmunoGen if a promising new cancer drug is approved.

MINYANVILLE ORIGINAL Shares of ImmunoGen (NASDAQ:IMGN) are dropping after the company disclosed what some investors see as disappointing royalty terms for a promising new cancer drug.

ImmunoGen is partnered with Swiss pharmaceutical giant Roche (PINK:RHHBY) in a licensing agreement for the development of a breast cancer treatment that the Food and Drug Administration is considering for approval. The drug, trastuzumab emtansine, or T-DM1, combines ImmunoGen's chemotherapy with Roche's Herceptin to better target cancer. Roche's Genentech subsidiary applied for FDA approval in August. Roche also applied for approval in Europe. Analysts expect the drug will be approved based on positive results from clinical studies.

Some analysts estimated earlier that ImmunoGen would earn 5% royalties on sales of the cancer drug -- assuming that it gets approved. In a securities filing Friday, ImmunoGen disclosed that its royalty payments in the US and outside the country begin at 3% of sales and only reach the 5% level if revenue jumps above $700 million in a given year.

The disclosure has analysts like Joel Sendek of Stifel Nicolaus revising his revenue estimates for ImmunoGen. After initially predicting annual royalty revenue of $2.4 million to $176 million between 2013 and 2018, Sendek now estimates ImmunoGen will receive $300,000 beginning in 2013 up to $126 million in 2018. Again, these figures are based on the drug actually get approved. Sendek has a hold rating on ImmunoGen's stock.

Shares of ImmunoGen fell more than 14% to $11.83 in midday trading Friday. The stock is up 2% on the year. It traded to almost $18 per share in July.

Herceptin targets a protein known as HER2 that promotes cancer growth. The combination therapy of T-DM1 is designed to deliver the chemo directly into cancer cells.

"We believe T-DM1 has the potential to rapidly become a highly successful product that makes a real difference," ImmunoGen CEO Daniel Junius said as the company released its quarterly results Friday.

In its fiscal first quarter, ImmunoGen lost more than $25 million, or $.30 per share, on $4 million in revenue. In addition to its Roche partnership, ImmunoGen has collaborations and license agreements with Sanofi (NYSE:SNY), Amgen (NASDAQ:AMGN), Novartis (NYSE:NVS), Eli Lilly (NYSE:LLY) and Bayer (PINK:BAYRY).

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos